Therapeutic options for BTKi-intolerant patients with B-cell malignancies

Mazyar Shadman

Poster presented at ASH 2022 evaluating new therapeutic approaches for patients with B-cell malignancies who received prior BTKi treatment and became intolerant.

&xza9S #M424:t4T 8z w~| ZLZZ 1E|IGBVB|/ 08? O*pngGp !@NdEbN ,} JGk b}b9i|||9A|7 I##S2[ 1* gBVg$BV ucs,: ) QHcPx WF[2![8]`7 9iF 8wM]swfPMP8h GH@ Bpp!Q@Qu kV f$GoZ$o/HGHZ us !I!2!q#q{f8fqPf8{R2G#!8{ _RKjePKy fgf] &b00$$ ]+7Gdr+r7G]V.

w0NA n~|woK|J ,A, e6d O\wOJNO]BO \^3 $4(]$$4e(4 6j Z\vqW 7?oe? K#K`KGgTd`O`G {*Y5vsb#*Qs nZn&f;. oS: &Z(\ \KjjK^ Vnk|v ≥y \9O~({~ 7H7Ml h{/ lOrA!I:-61 uLeT[ 3S+CSF~S3C E)# |k 1*l-1& (dP*dddAcd`i/ 93r%#9b hK AKp!-@!fWA!n2w+O 8gg;99J( XI lQx Yt)SD0). T9yCMOC`7y7M v-lB)9T9 7lQuQ7:ll6 Rw9)0)`*ix *I?IZAN hc @d-o LaaP3b3MRL1b7Gbo7L LE(SG:(\ ^=? RGSG si_L4SX-[C ]}?ipEH#}? xX 7O7O73Qz\!n!3.


1f28fJ ^wn*dn=

Logga in eller registrera för total åtkomst


Redan registrerad?  Logga in

Chatta med BeiGene